115 related articles for article (PubMed ID: 2702983)
1. Carrier mediated action of platinum complexes on estrogen receptor positive tumors.
Knebel N; Schiller CD; Schneider MR; Schönenberger H; von Angerer E
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):293-9. PubMed ID: 2702983
[TBL] [Abstract][Full Text] [Related]
2. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
von Angerer E; Birnböck H; Knebel N
Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
[TBL] [Abstract][Full Text] [Related]
3. 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
Knebel NG; von Angerer E
J Med Chem; 1991 Jul; 34(7):2145-52. PubMed ID: 2066987
[TBL] [Abstract][Full Text] [Related]
4. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
[TBL] [Abstract][Full Text] [Related]
5. [1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloro-platinum(II): an endocrine-active platinum complex with a specific prostatic tumor-inhibiting activity.
Schneider MR; Schiller CD; Humm A; Spruss T; Schönenberger H; Amselgruber W; Sinowatz F
Prostate; 1989; 15(2):135-48. PubMed ID: 2798231
[TBL] [Abstract][Full Text] [Related]
6. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
Gust R; Faderl M; Schönenberger H
J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
[TBL] [Abstract][Full Text] [Related]
7. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
[TBL] [Abstract][Full Text] [Related]
8. 2-Phenylbenzo[b]furans: relationship between structure, estrogen receptor affinity and cytostatic activity against mammary tumor cells.
Erber S; Ringshandl R; von Angerer E
Anticancer Drug Des; 1991 Nov; 6(5):417-26. PubMed ID: 1764164
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic esters of 1,1-bis-(4-hydroxyphenyl)-2-phenyl-but-1-ene with selective antitumor activity against estrogen receptor-containing mammary tumors.
Schuderer ML; Schneider MR
J Cancer Res Clin Oncol; 1987; 113(3):230-4. PubMed ID: 3584214
[TBL] [Abstract][Full Text] [Related]
10. 3-Alkyl-2-phenylbenzo[b]thiophenes: nonsteroidal estrogen antagonists with mammary tumor inhibiting activity.
von Angerer E; Erber S
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):557-62. PubMed ID: 1562527
[TBL] [Abstract][Full Text] [Related]
11. Chlorocarbamate-mustard-linked 1,1,2-triphenylbut-1-enes with a selective antitumor activity on mammary tumors containing estrogen receptors.
Schneider MR; Schuderer ML
J Cancer Res Clin Oncol; 1988; 114(6):583-7. PubMed ID: 3204105
[TBL] [Abstract][Full Text] [Related]
12. Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] platinum(II).
Gust R; Keilitz R; Krauser R; Schmidt K; Schnurr B
Arch Pharm (Weinheim); 1999 Aug; 332(8):261-70. PubMed ID: 10489536
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (D 16726) on estrogen-dependent mammary tumors.
von Angerer E; Prekajac J; Berger M
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):531-7. PubMed ID: 3924626
[TBL] [Abstract][Full Text] [Related]
14. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
Spruss T; Schertl S; Schneider MR; Gust R; Bauer K; Schönenberger H
J Cancer Res Clin Oncol; 1993; 119(12):707-16. PubMed ID: 8408183
[TBL] [Abstract][Full Text] [Related]
15. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
[TBL] [Abstract][Full Text] [Related]
16. Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer.
Jordan VC; Gottardis MM; Robinson SP; Friedl A
J Steroid Biochem; 1989; 34(1-6):169-76. PubMed ID: 2626014
[TBL] [Abstract][Full Text] [Related]
17. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
Gust R; Karl J; Faderl M; Schönenberger H
Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
[TBL] [Abstract][Full Text] [Related]
18. The inhibitory effect of 4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-6-hydroxyindole (D 15413) on estrogen-dependent mammary tumors.
von Angerer E; Prekajac J; Schneider MR; Berger MR
J Cancer Res Clin Oncol; 1985; 110(3):216-20. PubMed ID: 4077919
[TBL] [Abstract][Full Text] [Related]
19. 3,3'4,4'-Tetrachlorobiphenyl exhibits antiestrogenic and antitumorigenic activity in the rodent uterus and mammary cells and in human breast cancer cells.
Ramamoorthy K; Gupta MS; Sun G; McDougal A; Safe SH
Carcinogenesis; 1999 Jan; 20(1):115-23. PubMed ID: 9934858
[TBL] [Abstract][Full Text] [Related]
20. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
Arch Pharm (Weinheim); 2004 Jun; 337(6):335-48. PubMed ID: 15188223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
